Table 2

The effect of crt on cardiac function and body composition

Baseline6 weeks6 monthsP value
Clinical, functional, laboratory*
QOL score (median, range)48.0 (8.0–85.0)33.5 (0.0–73.0)23.5 (0.0–0.83)0.06
QRS (ms, median, range)162(120–212)145 (102–194)159 (112–214)0.02
6MWT (M, mean±SD)252.6±132.0277.1±145.2242.4±178.80.29
eGFR (ml/min/1.73 m2, median, range)52.0 (25.0–130.0)47.0 (24.0–105.0)52.7 (20.0–90.0)0.34
NT-pro-BNP (pmol/L, median, range)267.0 (75.0–4138.0)236.5 (27.0–3848.0)272.5 (15.0–1690.0)0.87
Body composition (median, range)
BMI (kg/m2)28.7 (22.4–41.9)28.5 (22.0–34.4)28.0 (22.4–35.7)0.39
Fat mass (kg)†31.4 (18.1–61.2)29.0 (18.9–61.2)29.1 (18.6–50.3)0.12
Relative fat mass†0.38 (0.23–0.54)0.34 (0.25–0.51)0.39 (0.28–0.52)0.09
Lean mass (kg)†52.3 (30.9–73.3)53.9 (31.9–75.0)50.5 (31.9–75.0)0.19
Waist circumference (cm)†98.2 (84.6–131.0)99.3 (76.0–119.4)100.1 (78.9–120.9)0.53
Echocardiography‡
LVESV (mL, median, range)125.8 (62.9–268.7)112.7 (52.8–210.8)95.2 (57.8–315.6)0.26
LVESV_BSA(mL, median, range)58.9 (38.7–128.0)56.8 (28.2–118.7)49.5 (30.6–131.5)0.26
LVEF (%, median, range)25.6 (9.7–35.4)29.4 (13.6–43.6)32.7 (14.4–41.7)0.14
  • *Based on patients able to have clinical, functional and laboratory assessments (baseline=25, 6 weeks=24, 6 months=22),

  • †Based on participants able/available to have BOD-POD assessment (baseline=25, 6 weeks=23, 6 months=20).

  • ‡Based non complete series of echocardiograms with biplane measurements.

  • BMI, body mass index; BOD POD, trade name of the device used; BSA, body surface area; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction ; LVESV, left ventricular end-systolic volume ; 6MWT, 6 min walk test; NT-pro-BNP, N-terminal probrain natriuretic peptide; QOL, quality of life.